Wiener Medizinische Wochenschrift

, Volume 162, Issue 11–12, pp 248–251 | Cite as

TBE—update on vaccination recommendations for children, adolescents, and adults

main topic

Summary

Vaccines against tick-born encephalitis (TBE) are well established in Europe. Two highly immunogenic and safe products are available, FSME-IMMUN and Encepur. Extensive research has been published regarding all aspects of standard and rapid immunization schedules, covaccination, and vaccine interchangeability. Long-term effectiveness and resulting recommendations for booster intervals remain topics of discussion. Vaccination is recommended in Switzerland and in Germany for adults and children living in, or travelling to, endemic areas. Austria has recommended universal vaccination since 1981. It is noteworthy that Austria is the only country in Europe that has experienced a decrease in caseload during the last 20 years. This is almost certainly due to the very high vaccine coverage rate of 86 %.

Keywords

Vaccination Immunization TBE Prevention 

FSME – Aktueller Stand der Impfempfehlungen im Kindes-, Jugend- und Erwachsenenalter

Zusammenfassung

Mit Encepur und FSME-Immun stehen in Europa zwei sehr sichere und immunogene Impfstoffe gegen FSME zur Verfügung. Zur Grundimmunsierung inklusive Schnellschema, Co-Vakzination und Austausch der Vakzinen liegen umfangreiche Studiendaten vor. In Diskussion bleiben die Dauer des Mindest-Langzeitschutzes und die daraus resultierenden Boosterabstände. Die Impfung wird in der Schweiz und in Deutschland bei Aufenthalt in Endemiegebieten empfohlen, in Österreich existiert seit 1981 ein universelles Impfprogramm. Hierbei ist Österreich das einzige Land in Europa, das in den letzten 20 Jahren stetig fallende FSME-Fallzahlen verzeichnen konnte. Dies ist mit hoher Wahrscheinlichkeit auf die sehr guten Durchimpfungsraten von 86 % zurückzuführen.

Schlüsselwörter

Impfung Immunisierung FSME Vorbeugung 

References

  1. 1.
    WHO. Vaccines against tick-borne encephalitis: WHO position paper. Weekly Epidemiological Record. 2011;86:241–56.Google Scholar
  2. 2.
    Holzmann H, Kundi M, Stiasny K, Clement J, McKenna P, Kunz C, et al. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J Med Virol. 1996;48:102–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Demicheli V, Debalini MG, Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst Rev. 2009:CD000977.Google Scholar
  4. 4.
    Schoendorf I, Ternak G, Oroszlan G, Nicolay U, Banzhoff A, Zent O. Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Hum Vaccin. 2007;3:42–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Paulke-Korinek M, Rendi-Wagner P, Kundi M, Laaber B, Wiedermann U, Kollaritsch H. Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection. Vaccine. 2009;27:7027–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine. 2005;23:3232–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Weinberger B, Keller M, Fischer KH, Stiasny K, Neuner C, Heinz FX, et al. Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50–90 years. Vaccine. 2010;28:3511–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Stiasny K, Holzmann H, Heinz FX. Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs. Vaccine. 2009;27:7021–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Andersson CR, Vene S, Insulander M, Lindquist L, Lundkvist A, Gunther G. Vaccine failures after active immunization against tick-borne encephalitis. Vaccine. 2010;28:2827–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine. 2007;25:7559–67.PubMedCrossRefGoogle Scholar
  11. 11.
    Rendi-Wagner P, Zent O, Jilg W, Plentz A, Beran J, Kollaritsch H. Persistence of antibodies after vaccination against tick-borne encephalitis. Int J Med Microbiol. 2006;296(Suppl 40):202–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Rendi-Wagner P, Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B, Kollaritsch H. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine. 2007;25:5097–5101.PubMedCrossRefGoogle Scholar
  13. 13.
    Plentz A, Jilg W, Schwarz TF, Kuhr HB, Zent O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur® Adults. Vaccine. 2009;27:853–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Wittermann C, Schondorf I, Gniel D. Antibody response following administration of two pediatric tick-borne encephalitis vaccines using two different vaccination schedules. Vaccine. 2009;27:1661–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Petri E, Gniel D, Zent O. Tick-borne encephalitis (TBE) trends in epidemiology and current and future management. Travel Med Infect Dis. 2010;8:233–45.PubMedCrossRefGoogle Scholar
  16. 16.
    Anonymous. Risikogebiete in Deutschland. Epid Bull. 2011;17:133–45.Google Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  1. 1.Berlin Center for Travel and Tropical MedicineBerlinGermany

Personalised recommendations